These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 15905710)

  • 1. The case for using 5-aminosalicyclates in Crohn's disease: pro.
    Hanauer SB
    Inflamm Bowel Dis; 2005 Jun; 11(6):609-12. PubMed ID: 15905710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Debate: should mesalamine be used in Crohn's disease?: comments and conclusions.
    Kamm MA
    Inflamm Bowel Dis; 2005 Jun; 11(6):616-7. PubMed ID: 15905712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG
    Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
    [No Abstract]   [Full Text] [Related]  

  • 4. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Hanauer S
    Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case against using 5-aminosalicyclates in Crohn's disease: con.
    Stange EF
    Inflamm Bowel Dis; 2005 Jun; 11(6):613-5. PubMed ID: 15905711
    [No Abstract]   [Full Text] [Related]  

  • 6. Mesalamine derivatives in the treatment of Crohn's disease.
    Harrell LE; Hanauer SB
    Gastroenterol Clin North Am; 2004 Jun; 33(2):303-17, ix-x. PubMed ID: 15177540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
    Neĭman KP; Rumiantsev VG
    Eksp Klin Gastroenterol; 2006; (3):56-60. PubMed ID: 17203844
    [No Abstract]   [Full Text] [Related]  

  • 8. [5-aminosalicylic acid for induction of remission or clinical response in Crohn's disease--a survey of a Cochrane review].
    Bjerrum JT; Munck LK; Nielsen OH
    Ugeskr Laeger; 2011 Aug; 173(35):2110-3. PubMed ID: 21884660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of 5-aminosalicylates in Crohn's disease: systematic review and meta-analysis.
    Ford AC; Kane SV; Khan KJ; Achkar JP; Talley NJ; Marshall JK; Moayyedi P
    Am J Gastroenterol; 2011 Apr; 106(4):617-29. PubMed ID: 21407190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
    Bonapace CR; Mays DA
    Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
    Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
    Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
    Feagan BG; Sandborn WJ
    Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
    Nørgård BM
    Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
    Sandborn WJ; Feagan BG
    Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion.
    Feagan BG
    Clin Gastroenterol Hepatol; 2004 May; 2(5):376-8. PubMed ID: 15118974
    [No Abstract]   [Full Text] [Related]  

  • 16. Mesalamine for prophylaxis of small bowel Crohn's disease recurrence.
    Bauer WM; Brzezinski A; Lashner BA
    Curr Gastroenterol Rep; 1999 Oct; 1(5):377-83. PubMed ID: 10980975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
    Doherty G; Katsanos KH; Burisch J; Allez M; Papamichael K; Stallmach A; Mao R; Berset IP; Gisbert JP; Sebastian S; Kierkus J; Lopetuso L; Szymanska E; Louis E
    J Crohns Colitis; 2018 Jan; 12(1):17-31. PubMed ID: 28981623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC; Hanauer SB
    Rev Gastroenterol Disord; 2004; 4(3):104-17. PubMed ID: 15359211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesalamine in the treatment of active Crohn's disease.
    Dignass A; Marteau P
    Gastroenterology; 2005 Jan; 128(1):245-6; author reply 246. PubMed ID: 15633152
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.